The ability of small nucleic acids to modulate gene expression via a range of processes has been widely explored.Compared with conventional treatments,small nucleic acid therapeutics have the potential to achieve long...The ability of small nucleic acids to modulate gene expression via a range of processes has been widely explored.Compared with conventional treatments,small nucleic acid therapeutics have the potential to achieve long-lasting or even curative effects via gene editing.As a result of recent technological advances,effcient small nucleic acid delivery for therapeutic and biomedical applications has been achieved,accelerating their clinical translation.Here,we review the increasing number of small nucleic acid therapeutic classes and the most common chemical modifications and delivery platforms.We also discuss the key advances in the design,development and therapeutic application of each delivery platform.Furthermore,this review presents comprehensive profiles of currently approved small nucleic acid drugs,including 11 antisense oligonucleotides(AsOs),2 aptamers and 6 siRNA drugs,summarizing their modifications,disease-specific mechanisms of action and delivery strategies.Other candidates whose clinical trial status has been recorded and updated are also discussed.We also consider strategic issues such as important safety considerations,novel vectors and hurdles for translating academic breakthroughs to the clinic.Small nucleic acid therapeutics have produced favorable results in clinical trials and have the potential to address previously"undruggable"targets,suggesting that they could be useful for guiding the development of additional clinical candidates.展开更多
基金supported by the 1.3.5 Project for Disciplines of Excellence,West China Hospital,Sichuan University(No.ZYGD23008)by the Frontiers Medical Center,Tianfu Jincheng Laboratory Foundation(No.TFJC202310005)by the Scientific Research and Innovation Team Program of Sichuan University of Science and Technology(No.SUSE652B003).
文摘The ability of small nucleic acids to modulate gene expression via a range of processes has been widely explored.Compared with conventional treatments,small nucleic acid therapeutics have the potential to achieve long-lasting or even curative effects via gene editing.As a result of recent technological advances,effcient small nucleic acid delivery for therapeutic and biomedical applications has been achieved,accelerating their clinical translation.Here,we review the increasing number of small nucleic acid therapeutic classes and the most common chemical modifications and delivery platforms.We also discuss the key advances in the design,development and therapeutic application of each delivery platform.Furthermore,this review presents comprehensive profiles of currently approved small nucleic acid drugs,including 11 antisense oligonucleotides(AsOs),2 aptamers and 6 siRNA drugs,summarizing their modifications,disease-specific mechanisms of action and delivery strategies.Other candidates whose clinical trial status has been recorded and updated are also discussed.We also consider strategic issues such as important safety considerations,novel vectors and hurdles for translating academic breakthroughs to the clinic.Small nucleic acid therapeutics have produced favorable results in clinical trials and have the potential to address previously"undruggable"targets,suggesting that they could be useful for guiding the development of additional clinical candidates.
